Abstract
Several patients suffer from the concomitant hepatitis C virus (HCV) infection and psoriasis. First-line treatment for patients with moderate to severe psoriasis and HCV includes ultraviolet (UV) phototherapy combined with topical therapy, such as topical corticosteroids, vitamin D3 derivatives, keratolytics, coal tars, and calcineurin inhibitors. Second-line treatment includes TNF inhibitors, together with consultation with a hepatologist.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Bonifati C, Lora V, Graceffa D, et al. Management of psoriasis patients with hepatitis B or hepatitis C virus infection. World J Gastroenterol. 2016;22(28):6444–55.
Caso F, Cantarini L, Morisco F, et al. Current evidence in the field of the management with TNF-α inhibitors in psoriatic arthritis and concomitant hepatitis C virus infection. Expert Opin Biol Ther. 2015;15(5):641–50.
Chun K, Afshar M, Audish D, et al. Hepatitis C may enhance key amplifiers of psoriasis. J Eur Acad Dermatol Venereol. 2016. Epub ahead of print.
Citro V, Fristachi R, Tarantino G. Extensive psoriasis induced by pegylated interferon: a case report. J Med Case Rep. 2007;1:86.
Frankel AJ, Van Voorhees AS, Hsu S, et al. Treatment of psoriasis in patients with hepatitis C: from the Medical Board of the National Psoriasis Foundation. J Am Acad Dermatol. 2009;61(6):1044–55.
Gabr SA, Berika MY, Alghadir AH. Apoptosis and clinical severity in patients with psoriasis and HCV infection. Indian J Dermatol. 2014;59(3):230–6.
Imafuku S, Naito R, Nakayama J. Possible association of hepatitis C virus infection with late-onset psoriasis: a hospital-based observational study. J Dermatol. 2013;40(10):813–8.
Katz HI, Waalen J, Leach EE. Acitretin in psoriasis: an overview of adverse effects. J Am Acad Dermatol. 1999;41(3 Pt 2):S7–12.
Navarro R, Vilarrasa E, Herranz P, et al. Safety and effectiveness of ustekinumab and antitumour necrosis factor therapy in patients with psoriasis and chronic viral hepatitis B or C: a retrospective, multicentre study in a clinical setting. Br J Dermatol. 2013;168(3):609–16.
Nyfors A, Dahl-Nyfors B, Hopwood D. Liver biopsies from patients with psoriasis related to photochemotherapy (PUVA): findings before and after 1 year of therapy in twelve patients. A blind study and review of literature on hepatotoxicity of PUVA. J Am Acad Dermatol. 1986;14(1):43–8.
Pompili M, Biolato M, Miele L, et al. Tumor necrosis factor-α inhibitors and chronic hepatitis C: a comprehensive literature review. World J Gastroenterol. 2013;19(44):7867–73.
Taylor C, Burns DA, Wiselka MJ. Extensive psoriasis induced by interferon alfa treatment for chronic hepatitis C. Postgrad Med J. 2007;76(896):365–7.
Zein NN, Etanercept Study Group. Etanercept as an adjuvant to interferon and ribavirin in treatment-naive patients with chronic hepatitis C virus infection: a phase 2 randomized, double-blind, placebo-controlled study. J Hepatol. 2005;42(3):315–22.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2017 Springer International Publishing AG
About this chapter
Cite this chapter
Darji, K., No, D.J., Amin, M., Wu, J.J. (2017). 54-Year-Old with Psoriasis and Hepatitis C Virus Infection. In: Wu, J. (eds) Clinical Cases in Psoriasis. Clinical Cases in Dermatology. Springer, Cham. https://doi.org/10.1007/978-3-319-52779-6_20
Download citation
DOI: https://doi.org/10.1007/978-3-319-52779-6_20
Published:
Publisher Name: Springer, Cham
Print ISBN: 978-3-319-52778-9
Online ISBN: 978-3-319-52779-6
eBook Packages: MedicineMedicine (R0)